Sirio Pharma targets women’s health from prenatal to menopause with new product range
02 Apr 2024 --- Sirio Pharma reveals it will launch a groundbreaking women’s health platform at Vitafoods Europe 2024, in Geneva, Switzerland (May 14-16). Sirio highlights that the innovative portfolio, comprising 25 formulations tailored to women’s health needs and life stages, is a significant milestone in women’s health and personalized nutrition.
Sirio says its new women’s health platform meets this demand with a diverse range of gummies and softgels addressing menstrual care, urinary tract infection protection, gut health, sleep health, weight management, fertility, morning sickness, prenatal and postnatal care and menopausal symptoms.
The products utilize Cargill’s Epicor gummy technology and include science-backed ingredients from ADM, KD Nutra and Gnosis by Lesaffre.
“Women’s health, focused on individual life stages, is the big trend of 2024,” says Sara Lesina, the general manager of Sirio Europe and Americas. “Our team researched this early to undertake all the complex formulation options, science and segmenting of product types.”
“Essentially, we have done the hard work so that our nutraceutical brand partners can launch more quickly to market with first-in-class products.”
Women-specific health needs
According to Sirio, the platform leverages its extensive global research and development capabilities to develop a premium range of products supported by branded ingredients, consumer trends, clinical data and stability studies. At the forefront of this launch are three key products for the women’s health market.
The three products to be introduced are the MenoBalance gummy, the Me&Mum postnatal softgel and the InnoFolate prenatal softgel.
MenoBalance utilizes Novasoy, a soy isoflavone from ADM that has been shown to reduce hot flashes and support bone health during menopause. This innovative and functional gummy marks the first successful delivery of Novasoy in a gummy format.
Paula Limena, the vice president of global marketing for health and wellness at ADM, states that the partnership allows ADM to combine Sirio’s “exceptional gummy manufacturing capabilities with our expertise in science-backed ingredients.”
“This collaboration enables us to create truly unique concepts, offering customers and consumers innovative and quality products that deliver on both taste and nutrition,” she adds.
Prenatal nutrition
The Me&Mum postnatal softgel is the result of the KD Nutra collaboration. It offers a comprehensive solution for new mothers, which addresses hormonal hair loss with a complex formulation of docosahexaenoic acid (DHA), vitamins, minerals and herbal extracts in a convenient softgel capsule.
Meanwhile, the InnoFolate prenatal softgel utilizes Sirio’s vegan Plantegrity technology and combines Gnosis by Lesaffre’s folate ingredient, Quatrefolic. The gummy combines Quatrefolic with DHA and other essential nutrients to support folate levels during pregnancy.
The new products will address prenatal and menopausal nutrition needs.Sirio states that these latest partnerships with branded ingredient suppliers allow the company to deliver personalized premium products backed by scientific evidence. By focusing on market-ready applications with proven efficacy, the company says it stands out in a competitive supplements market.
Focus on women’s nutrition
Sirio also points out that female consumers increasingly seek targeted nutritional supplements to address specific life stages and health concerns.
Sirio says its new women’s health platform meets this demand with a diverse range of gummies and softgels addressing menstrual care, UTI protection, gut health, sleep health, weight management, fertility, morning sickness, prenatal and postnatal care and menopausal symptoms.
Moreover, it says that many of the products in its women’s health platform offer vegetarian and carrageenan-free solutions and include pectin-based gummies in non-sugar or naturally sweetened options, catering to the preferences of today’s discerning consumers.
“We are constantly developing complex formulations made using the highest quality ingredients with the strongest evidence base, bioavailability and efficacy,” Lessina at Sirio concludes.
Edited by William Bradford Nichols
